Oxford BioMedica logo

OXB - Oxford BioMedica Share Price

545p -7.0  -1.3%

Last Trade - 03/04/20

Mid Cap
Market Cap £424.5m
Enterprise Value £406.9m
Revenue £63.6m
Position in Universe 503rd / 1834
Unlock OXB Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


OXB Revenue Unlock OXB Revenue

Net Income

OXB Net Income Unlock OXB Revenue

Normalised EPS

OXB Normalised EPS Unlock OXB Revenue

PE Ratio Range

OXB PE Ratio Range Unlock OXB Revenue

Dividend Yield Range

OXB Dividend Yield Range Unlock OXB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
OXB EPS Forecasts Unlock OXB Revenue
Profile Summary

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. The Company provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The Company's product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson's disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.

Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated September 20, 1996
Public Since November 15, 1996
No. of Shareholders: n/a
No. of Employees: 377
OXB Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for OXB
Upcoming Events for OXB
Thursday 23rd April, 2020
Full Year 2019 Oxford BioMedica PLC Earnings Release
Thursday 28th May, 2020 Estimate
Oxford BioMedica PLC Annual Shareholders Meeting
Similar to OXB
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.